The Pharmacological Guide to Trastuzumab

Dorota Bartusik-Aebisher
Department of Biochemistry and General Chemistry, Faculty of Medicine, University of Rzeszów, Rzeszów, Poland

David Aebisher
Department of Photomedicine and Physical Chemistry, Faculty of Medicine, University of Rzeszów, Rzeszów, Poland

Series: Pharmacology – Research, Safety Testing and Regulation
BISAC: MED071000, MED062000



Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick


Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:



This book provides a current review of the field of Trastuzumab pharmacology from a variety of chemical, biochemical, physiological, pharmacokinetical, pharmacodynamical, biophysical and medical perspectives. This book covers breast cancer treatment including current Trastuzumab therapy, radiation therapy and excision of tumors within the limits of healthy tissue. The text presents current knowledge and analysis of pertinent literature and knowledge. This book reports results from experimental models of HER2 oncogene overexpression and treatments which have been used in an effort to understand the relationship between HER2 and response to therapeutics.

In this book the HER2 oncogene has been extensively discussed as a prognostic factor and as a predictor of response to chemotherapy and endocrine therapy. The book includes data regarding the expression of HER2 oncogene in lung cancer and response to trastuzumab alone or in combination with chemotherapeutic agents. The interaction of HER2 with others drugs such as alkylating agents, platinum analogs and topoisomerase inhibitors, as well as additive interactions with taxanes, anthracyclines and some metabolites and antimetabolites are presented. Special cardiological supervision for patients with an increased risk of cardiotoxicity that have hypertension, ischemic heart disease, hypothyroidism or are heavy smokers during adjuvant trastuzumab therapy will also be reviewed.
(Imprint: Nova Medicine and Health)


Chapter 1. Trastuzumab: Characteristics

Chapter 2. Trastuzumab: Therapeutic Indications

Chapter 3. Trastuzumab: Pharmacodynamic Properties

Chapter 4. Trastuzumab: Pharmacokinetic Properties

Chapter 5. Trastuzumab: Interaction with Other Medicinal Products


You have not viewed any product yet.